ADVIC.PA

Advicenne S.A. [ADVIC.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ADVIC.PA Stock Summary

In the News

ADVIC.PA Financial details

Company Rating
-
Market Cap
0
Income
-10.39M
Revenue
2.74M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
32
Optionable
No
Shortable
Yes
Earnings
31 Mar 2022
P/E
-3.87
Forward P/E
-
PEG
1.85
P/S
-
P/B
3.14
P/C
-
P/FCF
-
Quick Ratio
3.31
Current Ratio
4.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-13.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
14.87%
Revenue last 5Y
19.85%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
16.67%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-60%
ROE
-59%
ROC
-0.82%
Gross Margin
-543%
Oper. Margin
-733%
Profit Margin
-686%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.07-6.62
52W High
+8.33%
52W Low
+8.33%
RSI
-
Rel Volume
1.4
Avg Volume
45.76K
Volume
63.83K
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
24.52%
-
-
-
-
Beta
1.43189
-
-
Volatility
0%, 0.24%
Prev Close
0%
Price
6.5
Change
6.56%

Something similar

Top by Market Cap
AMZN
FXAIX
BRH.DE
ABEC.DE
3V64.DE
Same Sector
STIM
DRW3.DE
IBAB.BR
ARDS
039840.KQ
Check Those
CISIX
VRL.DE
603393.SS
2471.TW
MCEM
Similar Market Cap
HYXU
BHFAP
WPF
IPCALAB.NS
ACCON.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 45.76K
  • Employee 32
  • CEO Dr. Andr Ulmann M.D., Ph.D.
  • Headquarters Nimes,OCCITANIE,FR
  • IPO Date 2017-12-06
  • Website https://www.advicenne.com

Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.